Ad
related to: pde4 inhibitors psoriasishealth.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
A phosphodiesterase-4 inhibitor, commonly referred to as a PDE4 inhibitor, is a drug used to block the degradative action of phosphodiesterase 4 (PDE4) on cyclic adenosine monophosphate (cAMP). It is a member of the larger family of PDE inhibitors. The PDE4 family of enzymes are the most prevalent PDE in immune cells. They are predominantly ...
Apremilast, sold under the brand name Otezla among others, is a medication for the treatment of certain types of psoriasis and psoriatic arthritis. [4] The drug acts as a selective inhibitor of the enzyme phosphodiesterase 4 (PDE4). [4] It is taken by mouth. [4]
Roflumilast, sold under the brand name Daxas among others, is a medication used for the treatment of chronic obstructive pulmonary disease, [4] plaque psoriasis, [5] seborrheic dermatitis, [6] and atopic dermatitis. [5] It acts as a selective, long-acting inhibitor of the enzyme phosphodiesterase-4 (PDE-4). [10] It has anti-inflammatory effects ...
Apremilast, used to treat psoriasis and psoriatic arthritis. Crisaborole, used to treat atopic dermatitis. Glaucine, an aporphine alkaloid, low-potency PDE4 inhibitor, calcium channel blocker, dopamine antagonist and 5-HT2A positive allosteric modulator, used as antitussive in Eastern Europe and Iceland.
Mufemilast (Hemay005) is a small-molecule inhibitor of phosphodiesterase 4. It is developed by Hemay Pharmaceutical for psoriasis. [1] [2] [3] References
Crisaborole is a phosphodiesterase-4 inhibitor, mainly acting on phosphodiesterase 4B (PDE4B), which causes inflammation. [6] Chemically, crisaborole is a phenoxybenzoxaborole . [ 6 ] Inhibition of PDE4B appears to suppress the release of tumor necrosis factor alpha (TNFα), interleukin-12 (IL-12), IL-23 and other cytokines , proteins believed ...
Bimekizumab, sold under the brand name Bimzelx (/ b ɪ m ˈ z ɛ l ɪ k s / bim-ZEL-iks), is a humanized anti-IL17A, anti-IL-17F, and anti-IL17AF monoclonal antibody [6] [7] that is used to treat plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa.
The Psoriasis Area Severity Index (PASI) was reduced significantly better than under the comparator treatments. 81–82% of patients under briakinumab, 40–56% under etanercept, and 7% under placebo reached PASI reduction of at least 75%. [9] No head-to-head studies against ustekinumab, the other IL-12/23 inhibitor, are available.
Ad
related to: pde4 inhibitors psoriasishealth.com has been visited by 10K+ users in the past month